Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ARG2 | P78540 | 11/20 | 0.45 |
| ▸ | ARG1 | P05089 | 11/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | GGT1 | P19440 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23010905 | 0.91 | ARG1 (0.48) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL6759254 | 0.90 | MEN1 (0.68) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL6759253 | 0.90 | MEN1 (0.68) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL24163861 | 0.90 | MEN1 (0.68) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL1399007 | 0.89 | ALDH1A1 (0.73) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL9005565 | 0.89 | ALDH1A1 (0.73) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL20156725 | 0.89 | ARG2 (0.52) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL21239452 | 0.87 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL21239451 | 0.87 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL77047 | 0.87 | ARG2 (0.52) | MEN1ALDH1A1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273710-A1 | Highly Potent Full and Partial Agonists and Antagonists of the Nociceptin/Orphanin FQ Receptor | GUERRINI REMO | 2010-10-28 | — | — | US | claimed |
| EP-1851241-A2 | HIGHLY POTENT FULL AND PARTIAL AGONISTS AND ANTAGONISTS OF THE NOCICEPTIN/ORPHANIN FQ RECEPTOR | Menarini International Operations Luxembourg S.A. (LU) | 2007-11-07 | — | — | EP | claimed |
| EP-1337551-B1 | SUBSTANCE P ANALOGS FOR THE TREATMENT OF CANCER | DABUR PHARMA LTD (IN) | 2007-01-03 | — | — | EP | claimed |
| WO-2006087340-A2 | HIGHLY POTENT FULL AND PARTIAL AGONISTS AND ANTAGONISTS OF THE NOCICEPTIN/ORPHANIN FQ RECEPTOR | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-08-24 | — | — | WO | claimed |
| US-6989371-B1 | Bombesin analogs for treatment of cancer | DABUR RESEARCH FOUNDATION (IN) | 2006-01-24 | — | — | US | claimed |
| US-6596692-B1 | Novel synthetic peptide analogs that are antagonists to Substance P, substance P like peptides and related peptides and are useful for the treatment of cancer, especially colon cancer | DABUR RESEARCH FOUNDATION (IN) | 2003-07-22 | — | — | US | claimed |
| EP-0918534-A4 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIV PITTSBURGH (US) | 2001-10-10 | — | — | EP | claimed |
| US-5952294-A | OLIGOPEPTIDE ATTACHED TO AMINO, HYDROXY OR THIOL FUNCTIONS OF THERAPEUTIC AGENT, E.G. ARA-C, TO EXTEND ITS BIOLOGICAL ACTIVE LIVE IN VIVO; CONTROLLING THE KINETICS AND METABOLISM; LEUKEMIA; VIRICIDES; ANTITUMOR/-CARCINOGENIC AGENTS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0918534-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1998004277-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1998-02-05 | — | — | WO | claimed |
| US-12465660-B2 | Compositions and methods for cancer imaging and radiotherapy | VECT-HORUS (FR) | 2025-11-11 | — | — | US | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-20240100204-A1 | COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY | VECT-HORUS (FR) | 2024-03-28 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0534774-A1 | 5,5-Dialkyl hydantoins for promoted acid gas scrubbing processes | EXXON CHEMICAL PATENTS INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| EP-0446706-A2 | Peptides with tachykinin-agonistic or -antagonistic activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | MEN1 3072/4885ALDH1A1 4565/4885CYP1A2 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.